Curis, Inc. registered up to 33,333,360 common shares for resale by selling stockholders, including shares issuable upon exercise of October 2026 Pre-Funded Warrants and October 2026 Common Warrants sold in the October 2026 Private Placement.
CRIS · Curis Inc
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt regarding the Company’s ability to continue as a going concern.”View the 10-Q filed Nov 13, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 67%
- Last earnings
- Nov 12, 2026
- Latest filing
- 10-Q · Nov 13
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Curis, Inc. says $5.0 million of cash plus approximately $7.5 million from the October 2026 Private Placement fund operations into the first quarter of 2027. Substantial going-concern doubt remains; Curis appealed Nasdaq’s November 2, 2026 delist determination.
Curis reported a third-quarter net loss of $8.1 million, no revenue, and $5.0 million cash as of September 30, 2026; it believes financing will fund operations into the first quarter of 2027, while 2 emavusertib studies continue enrolling.
Curis reported an 86% response rate in seven BTK-naive primary CNS lymphoma patients and responses in 10 of 39 salvage-line patients. Full enrollment is expected in 2027, followed by an NDA filing in 2028.
Nasdaq notified Curis, Inc. on November 2, 2026 that common stock closed below the minimum $1.00 per share for 30 business days. A July 6, 2026 1-for-20 reverse stock split left the company ineligible for a compliance period.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 12, 2026TL;DR. PCNSL data showed meaningful response rates and support the potential for accelerated approval, while the CLL study reached 12 patients with initial data expected in December 2026. Curis also funded operations into the first quarter of 2027, but reported no revenue, larger net losses, insufficient cash for the next 12 months, and a potential PCNSL NDA filing in 2028.
- + Updated PCNSL data showed an 86% overall response rate in BTK-naïve patients.
- + The combination produced a 26% overall response rate in BTKi-experienced PCNSL patients.
- + FDA and EMA guidance indicated the registrational PCNSL study could support accelerated-approval applications.
- + The CLL study enrolled 12 patients, with initial data expected in December 2026.
- + Existing cash and October private-placement proceeds were expected to fund operations into the first quarter of 2027.
- + Third-quarter research and development expense decreased to $5.6 million from $6.4 million.
- − Curis reported no revenue for the quarter or year ended September 30, 2026.
- − Third-quarter net loss was $8.1 million, compared with $7.7 million in the prior-year period.
- − Nine-month net loss was $40.9 million, compared with $26.9 million in the prior-year period.
- − Nine-month other expense increased to $10.7 million from $1.6 million.
- − Curis lacked sufficient cash to support current operations for the next 12 months and said it would require substantial additional funding.
- − PCNSL full enrollment was anticipated in 2027, with an NDA filing anticipated in 2028.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| BTK-naïve patients | 7 | July 2026 | — |
| BTKi-experienced patients | 39 | July 2026 | — |
| ongoing studies | 2 | currently | — |
| Shares of common stock sold under the 2024 Sales Agreement | 107,449 | the three months ended September 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CRIS
this stock
Curis Inc
|
$4.06M | — | +31.5% | — | 10.8% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 13, 2026
- This year
- 31
Curis, Inc. registered up to 33,333,360 common shares for resale by selling stockholders, including shares issuable upon exercise of October 2026 Pre-Funded Warrants and October 2026 Common Warrants sold in the October 2026 Private Placement.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CRIS | -4.0% | +10.5% | -95.7% | -28.8% | -97.8% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +4.5% | +19.8% | -86.6% | -20.1% | -99.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.